民生证券股份有限公司 关于博瑞生物医药（苏州）股份有限公司 2023 年度募集资金存放与使用情况的专项核查报告 民生证券股份有限公司（以下简称"保荐机构"或"民生证券"）作为博瑞 生物医药（苏州）股份有限公司（以下简称"博瑞医药"或"公司"）首次公开 发行股票并上市持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》、 《上海证券交易所科创板股票上市规则》等有关规定，对博瑞医药 2022 年度募 集资金存放与使用情况进行了核查，并发表核查意见如下： 一、集资金的基本情况 （一） 2019 年首次公开发行股票募集资金情况 1、实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意博瑞生物医药（苏州）股份有限公司 首次公开发行股票注册的批复》（证监许可〔2019〕1883 号）核准，并经上海证 券交易所同意，公司于 2019 年 10 月首次公开发行普通股（A 股）41,000,000 股， 每股发行价格为人民币 12.71 元，募集资金总额 521,110,000.00 元，扣除承销及 保荐费用、会计师费用、律师费用、信息披露费用及其他发行手续费共计人民币 81,125,361.23 元后，本次 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2024-022 博瑞生物医药（苏州）股份有限公司 第三届监事会第二十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 监事会认为：公司 2023 年年度报告的编制和审议程序符合法律法规和《公 司章程》的规定。报告内容真实、准确、完整的反映了公司 2023 年经营的实际 情况，未发现参与 2023 年年度报告编制和审议人员有违反保密规定的行为。监 事会保证公司 2023 年年度报告及其摘要披露的信息真实、准确、完整，其中不 存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和 完整性承担个别及连带责任。 1 表决结果：5 票同意；0 票反对；0 票弃权。 一、监事会会议召开情况 博瑞生物医药（苏州）股份有限公司（以下简称"公司"或"博瑞医药"） 第三届监事会第二十三次会议于 2024 年 4 月 26 日以现场会议加通讯表决方式在 C27 栋会议室召开。本次会议通知以及相关材料已于 2024 年 4 月 16 日以邮件方 式送达公司全体 ...

博瑞生物医药（苏州）股份有限公司 二、董事会对独立董事独立性情况的评估意见 董事会对独立董事独立性自查情况的专项报告 根据中国证券监督管理委员会《上市公司独立董事管理办法》《上海证券交 易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等要求，博瑞生物医药（苏州）股份有限公司（以下简称"公 司"）董事会就公司在任独立董事 RUYI HE（何如意）先生、许冬冬先生、吴英 华女士的独立性情况进行评估，详情如下： 一、独立董事独立性自查情况 公司现有独立董事 3 人，分别为 RUYI HE（何如意）先生、许冬冬先生、吴 英华女士。根据《上市公司独立董事管理办法》《上海证券交易所科创板股票上 市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 相关规定，公司独立董事对自身的独立性情况进行了自查，并将自查情况提交了 董事会。自查结果显示，公司独立董事均符合《上市公司独立董事管理办法》对 独立性的相关要求，与公司以及公司主要股东之间不存在利害关系或其他可能妨 碍其进行独立客观判断的关系，能够独立履行职责，不受公司及其主要股东、实 际控制人等单位或个人的影响。 ...

作为博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"或"公司"） 的独立董事，2023 年度本人严格按照《公司法》《证券法》《上市公司独立董事 管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 《公司章程》等相关规定，认真履行职责，及时了解公司运营情况，积极出席公 司股东大会、董事会及专门委员会相关会议，并对审议的相关事项发表了独立、 客观的意见。本人从维护公司整体利益出发，充分发挥专业特长，为公司的经营 发展提出合理化建议，促进公司健康持续发展，切实维护了公司和股东特别是中 小股东的合法权益。现将 2023 年度任期内履职情况汇报如下： 一、独立董事的基本情况 （一）本人工作履历、专业背景以及兼职情况 RUYI HE（何如意），1961 年 3 月出生，美国国籍，医学博士。曾任职于中 国医科大学附属第一医院、美国国家卫生研究院、美国 Howard 大学医学院附属 医院、美国 FDA 新药审评办公室消化及罕见病药物审评部、CFDA 药品评审中 心等；现任国投创新医疗健康首席科学家，荣昌生物制药（烟台）股份有限公司 执行董事、首席医学官、临床研究主管，苏州泽璟生物制药股份有限公 ...

Financial Performance - The company achieved operating revenue of CNY 1,179,517,532.47, representing a year-on-year growth of 15.94%[11] - The net profit attributable to shareholders decreased by 15.51% to CNY 20,246.60 million, while the net profit after deducting non-recurring gains and losses fell by 12.79% to CNY 18,631.27 million[11] - The cash flow from operating activities decreased by 37.43% to CNY 194,765,466.05, reflecting potential liquidity challenges[12] - The company reported a significant increase in financial expenses by 146.34% to CNY 24,140,439.00, which may impact profitability[12] - The company reported a total initial investment in derivatives of CNY 104,012,300.00, with a fair value loss of CNY 1,352,268.00 during the reporting period[42] - The company reported total assets of 571.92 million yuan and net assets of 277.19 million yuan, with operating revenue of 701.75 million yuan and net profit of 78.42 million yuan[76] Research and Development - Research and development expenses increased by 20.08% to CNY 248,592,240.65, indicating a focus on innovation[12] - The company reported R&D investment of ¥6,345,561,313.78, accounting for 29.83% of operating revenue[36] - The company's R&D investment as a percentage of net assets is 10.50%[36] - The company’s R&D investment capitalization ratio is 0.00%[36] - The company is focusing on expanding its market presence through professional exhibitions, online promotion, and direct visits to clients[37] - The company has several products in various stages of development, including BGC0228 in clinical phase I and BGM0504 in clinical phase II[33] - The company aims to enhance collaboration with clients by providing new product information and maintaining communication on product needs[38] - The company will explore the combination of GLP-1 drugs with other targets to address current clinical pain points in chronic metabolic diseases[95] - The company will adopt lean R&D strategies, focusing on high-innovation and clinically valuable pipelines in the innovative drug sector[95] Market Strategy and Expansion - The company is committed to internationalization, integrating global standards in product development, quality control, and market expansion[70] - The company aims to enhance its market share in China, Europe, the U.S., Japan, South Korea, and "Belt and Road" countries, focusing on a multi-dimensional global supply chain[84][85] - The company plans to adopt a diversified marketing strategy, including participation in national generic drug procurement to increase hospital coverage of its products[85] - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[125] - The company plans to enhance its digital marketing strategy, allocating an additional $5 million to increase brand awareness and customer engagement[125] Environmental Responsibility - The total greenhouse gas emissions from the company's subsidiaries in 2023 amounted to 47,628.89 tons of CO2 equivalent[131] - The company has implemented energy-saving measures, including the use of variable frequency chillers and regular replacement of outdated equipment, to optimize energy consumption[132] - The company emphasizes strict adherence to energy conservation laws and regulations during its operations[132] - The company is committed to controlling waste and pollutant emissions as part of its environmental management strategy[136] - The company has established a comprehensive environmental management system in place to address waste and pollution control[137] - The company has received various environmental permits, including pollution discharge permits valid until 2028[140] - The company has established a complete wastewater treatment system to manage various types of wastewater[184] - The company processes production wastewater to meet standards before discharge, ensuring compliance with environmental regulations[199] Governance and Compliance - The company has established a governance structure involving the shareholders' meeting, board of directors, and supervisory board[168] - The company strictly adhered to its information disclosure management system, ensuring timely and accurate reporting of significant matters[169] - The company has maintained effective internal controls over financial and non-financial reporting during the reporting period[154] - The company has no significant deficiencies in internal control during the reporting period[180] - The company actively promotes ESG governance and has entrusted the board of directors with overseeing related matters[172] Employee Management - The total number of employees is 1,155, with 753 in production, 270 in technical roles, and 29 in sales[157] - The employee education breakdown includes 13 PhD holders, 118 master's degree holders, 461 bachelor's degree holders, 303 associate degree holders, and 260 with high school or lower education[145] - The company has established a fair and effective performance evaluation system to ensure internal equity in salary growth based on project difficulty and duration[145] - The company has implemented a scientific and reasonable salary management system to ensure fair and motivating compensation distribution[145] - The company has established a training program to enhance employee skills and management capabilities, including customized training for mid-to-senior level staff[157] Financial Strategies and Dividends - The company plans to utilize part of the temporarily idle raised funds for cash management as approved in the board meeting on October 26, 2023[113] - In 2022, the company distributed a cash dividend of 0.114 RMB per share, totaling 48,161,051.38 RMB, based on a total share capital of 422,465,363 shares[146] - For the 2023 dividend plan, the company plans to distribute 0.96 RMB per 10 shares, amounting to a total of 40,521,897.60 RMB, based on 422,103,100 shares eligible for distribution[147] - The company has established clear and transparent dividend standards and procedures, ensuring the protection of minority shareholders' rights[189] - The company has not proposed a cash profit distribution plan despite reporting profits available for distribution to shareholders[189] Strategic Acquisitions and Investments - A strategic acquisition of a smaller biotech firm was completed, valued at $50 million, aimed at enhancing R&D capabilities[125] - The company invested $30 million in new technology development to improve production efficiency and reduce costs by 15%[125] - The company plans to increase the investment in the Taixing Phase II project from ¥310 million to ¥500 million[40] Risk Management - The company reported a market risk due to significant fluctuations in foreign exchange rates, which could lead to potential losses[43] - The company has implemented strict internal control measures to manage risks associated with foreign exchange derivatives trading, including regular monitoring and reporting to management[43]

| 修订前 | 修订后 | | --- | --- | | 第二十五条 公司收购本公司股份，可以选 | | | 择下列方式之一进行： | 第二十五条 公司收购本公司股份，可以通过 | | （一）证券交易所集中竞价交易方式； | 公开的集中交易方式，或者法律、行政法规 | | （二）要约方式； | 和中国证监会认可的其他方式进行。 | | （三）中国证监会认可的其他方式。 | | | 第二十六条 公司因本章程第二十二条第 | 第二十六条 公司因本章程第二十四条第 | | （一）项、第（二）项规定的情形收购本公 | （一）项、第（二）项规定的情形收购本公 | | 司股份的，应当经股东大会决议；因第（三） | 司股份的，应当经股东大会决议；因第（三） | | 项、第（五）项、第（六）项规定的情形收 | 项、第（五）项、第（六）项规定的情形收 | | 购本公司股份的，依照公司章程的规定，应 | 购本公司股份的，可以依照公司章程的规定 | | 当经三分之二以上董事出席的董事会会议 | 或者股东大会的授权，应当经三分之二以上 | | 决议。 | 董事出席的董事会会议决议。 | | 公司依照本章程第二十三条收购本公司股 | ...

博瑞生物医药（苏州）股份有限公司 走进博瑞医药 环境、社会及治理（ESG）报告 2 3 博瑞生物医药（苏州）股份有限公司 关于本报告 关于本报告 报告简介 数据说明 本报告是博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药""公司""我们"）发布的第三份 《社会责任报告》及第一份《环境、社会及治理报告》。报告本着客观、规范、透明和全面的原则，详细披露 了 2023 年博瑞医药在环境保护、社会责任、公司治理等领域的实践和绩效。 时间范围 本报告的时间范围是 2023 年 1 月 1 日至 2023 年 12 月 31 日，为增强报告的可比性和完整性，部分内容 超出上述范围。 报告范围 本报告以博瑞医药为主体，涵盖博瑞医药及其全资子公司、控股子公司，除特别说明外，本报告范围与本 公司的财务报告合并报表范围保持一致。 本报告中所采用的信息与数据来自于博瑞医药正式文件或统计数据，本公司承诺本报告不存在任何虚假记 载或误导性陈述，并对报告内容的真实性、准确性和完整性负责。 指代说明 | 博瑞医药、公司、我们、本公司 | 博瑞生物医药（苏州）股份有限公司 | | --- | --- | | 博瑞泰兴 | 博瑞生物医药 ...

民生证券股份有限公司 关于博瑞生物医药（苏州）股份有限公司 2024年度申请综合授信额度及提供担保事项的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为博瑞 生物医药（苏州）股份有限公司（以下简称"博瑞医药"或"公司"）持续督导 的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则》《上海证券交易所科创板上市公司自律监管指引第1号—规范运 作》《科创板上市公司持续监管办法（试行）》等法律法规，对公司2024年度申 请综合授信额度及博瑞医药及合并报表范围内公司相互提供担保事项进行了审 慎核查，发表意见如下： 一、情况概述 为满足公司正常生产经营的需要，在综合考虑年度生产经营安排、货款到期、 票据使用等情况下，博瑞医药及合并报表范围内公司2024年度拟向相关银行申请 不超过25亿元人民币的综合授信额度，授信品种包括但不限于流动资金贷款、项 目贷款、开立银行承兑汇票、开立信用证、保函、贸易融资等有关业务。在前述 授信最高额度内，博瑞医药及公司相互提供担保。 1 | | 发；医药中间体销售；销售本公司生产的产品；从事上述商品和技术的 | | | --- | -- ...

证券代码：688166 证券简称：博瑞医药 公告编号：2024-021 博瑞生物医药（苏州）股份有限公司 第三届董事会第二十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）第三届董事会第二 十五次会议于 2024 年 4 月 26 日以现场会议加通讯表决方式在 C27 栋会议室召 开。本次会议通知以及相关材料已于 2024 年 4 月 16 日以邮件方式送达公司全体 董事。 本次会议应出席董事 9 名，实到 9 名，会议由袁建栋先生召集和主持。本次 会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和《公司章 程》的规定。 二、董事会会议审议情况 （一）审议通过《2023 年董事会工作报告》 本议案尚需提交公司 2023 年年度股东大会审议。 （四）审议通过《2023 年度内部控制评价报告》 表决结果：9 票同意；0 票反对；0 票弃权。 本议案尚需提交公司 2023 年年度股东大会审议。 （二）审议通过《2023 年总 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 340,133,145.78, representing an increase of 11.54% compared to the same period last year[4]. - The net profit attributable to shareholders decreased by 9.47% to CNY 64,069,918.71, while the net profit after deducting non-recurring gains and losses decreased by 7.89% to CNY 64,214,448.31[4]. - Total operating revenue for Q1 2024 reached RMB 340,133,145.78, an increase of 11.5% compared to RMB 304,937,396.25 in Q1 2023[19]. - Net profit for Q1 2024 was RMB 70,586,962.95, a decrease of 6.7% compared to RMB 75,605,622.55 in Q1 2023[19]. - Total comprehensive income for Q1 2024 was ¥59.52 million, compared to ¥66.04 million in Q1 2023, reflecting a decrease of 9.8%[48]. Cash Flow and Assets - The net cash flow from operating activities surged by 492.42% to CNY 148,461,770.92, primarily due to an increase in received payments compared to the previous year[5]. - Cash and cash equivalents at the end of Q1 2024 were approximately ¥970.96 million, slightly down from ¥989.27 million at the end of Q1 2023[51]. - The company's cash and cash equivalents were CNY 984.47 million, down from CNY 998.05 million at the end of 2023[44]. - As of March 31, 2024, the company's total assets amounted to CNY 5.09 billion, compared to CNY 5.03 billion at the end of 2023[45]. - The company's fixed assets increased to CNY 825.91 million from CNY 718.12 million year-on-year[45]. Research and Development - Research and development expenses totaled CNY 65,047,828.56, an increase of 33.68%, accounting for 19.12% of operating revenue, up by 3.16 percentage points[4]. - The company is committed to a "R&D-driven" strategy, focusing on innovative drugs and inhalation formulations[5]. - The company completed BE trials for the inhaled form of Budesonide and is progressing with other inhalation products[56]. - The company has received ethical approval for Phase II clinical trials for BGM0504 injection for weight loss and type 2 diabetes treatment[56]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,553[23]. - Major shareholder Yuan Jiandong holds 26.87% of the company's shares, while Zhong Weifang holds 5.34%[26]. - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[26]. Market and Product Development - The company submitted 9 new domestic patent applications and obtained 6 new domestic patent authorizations in Q1 2024, bringing the total patent applications to 462[12]. - The construction of the Taixing raw material and formulation production base (Phase I) has been completed and accepted, while Phase II is undergoing environmental acceptance testing[13]. - The company received drug registration certificates for several products, including the injection of Carboprost Tromethamine and approvals for various raw materials in both domestic and international markets[29]. - The company plans to continue expanding its market presence and investing in new technologies[24]. Operating Costs and Revenue Breakdown - Total operating costs for Q1 2024 were RMB 267,341,183.31, up 16.6% from RMB 229,202,715.92 in Q1 2023[19]. - Product sales revenue reached CNY 303.57 million, up 13.30% year-on-year, with raw material drug revenue at CNY 246.99 million (up 11.67%) and formulation product revenue at CNY 56.58 million (up 21.02%)[27]. - Technical revenue decreased by 34.90% year-on-year to CNY 16.04 million, while equity sharing revenue increased by 10.49% to CNY 13.66 million[27]. - The company experienced a loss in investment income of RMB 4,545,946.74, compared to a loss of RMB 1,552,441.38 in the previous year[19]. Earnings Per Share - Basic and diluted earnings per share for Q1 2024 were both ¥0.15, down from ¥0.17 in Q1 2023[48].